Human Genome Epidemiology Literature Finder
Records 1 - 29 (of 29 Records) |
Query Trace: Cost-effectiveness analysis[original query] |
---|
Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis. Thrombosis and haemostasis 2000 Nov 84 (5): 752-7. Marchetti M, Pistorio A, Barosi |
Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Medical decision making : an international journal of the Society for Medical Decision Making 0 22 (2): 108-24. Eckman Mark H, Singh Sushil K, Erban John K, Kao Gra |
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004 Jun 14 (6): 335-42. Hughes Dyfrig A, Vilar F Javier, Ward Charlotte C, Alfirevic Ana, Park B Kevin, Pirmohamed Mun |
Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. The Journal of rheumatology 2006 Jul 33 (7): 1266-74. Kim Seong-Kyu, Jun Jae-Bum, El-Sohemy Ahmed, Bae Sang-Che |
Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health technology assessment (Winchester, England) 2006 Apr 10 (11): 1-110. Wu O, Robertson L, Twaddle S, Lowe G D O, Clark P, Greaves M, Walker I D, Langhorne P, Brenkel I, Regan L, Greer |
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2008 Jan 10 (1): 231-40. Welton Nicky J, Johnstone Elaine C, David Sean P, Munafò Marcus |
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antiviral therapy 2012 Dec . Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA |
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. Journal of the National Cancer Institute 2012 Dec 104 (23): 23. Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV |
Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. Molecular diagnosis & therapy 2012 Dec 16 (6): 389-99. Djalalov Sandjar, Yong Jean, Beca Jaclyn, Black Sandra, Saposnik Gustavo, Musa Zahra, Siminovitch Katherine, Moretti Myla, Hoch Jeffrey |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PloS one 2013 8 (3): e55917. Wang Siying, Peng Liubao, Li Jianhe, Zeng Xiaohui, Ouyang Lihui, Tan Chongqing, Lu Qio |
Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis care & research 2015 Feb 67 (2): 280-7. Park Dong-Jin, Kang Ji-Hyoun, Lee Jeong-Won, Lee Kyung-Eun, Wen Lihui, Kim Tae-Jong, Park Yong-Wook, Park Sung-Hwan, Lee Shin-Se |
Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenetics and genomics 2015 Feb 25 (2): 60-72. Kapoor Ritika, Martinez-Vega Rosario, Dong Di, Tan Sharlene Yanying, Leo Yee-Sin, Lee Cheng-Chuan, Sung Cynthia, Ng Oon-Tek, Archuleta Sophia, Teo Yik-Yi |
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. The European journal of health economics : HEPAC : health economics in prevention and care 2015 Sep . Arrieta Oscar, Anaya Pablo, Morales-Oyarvide Vicente, Ramírez-Tirado Laura Alejandra, Polanco Ana |
HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience. Pharmacogenetics and genomics 2016 May . Ruiz-Iruela Cristina, Padullés-Zamora Núria, Podzamczer-Palter Daniel, Alonso-Pastor Arnald, Candás-Estébanez Beatriz, Alía-Ramos Pedro, Padró-Miquel Ariad |
Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China. Journal of medical economics 2016 Nov 19 (11): 1056-1060. Xuan J W, Song R L, Xu G X, Lu W Q, Lu Y J, Liu |
Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer. Clinical lung cancer 2016 Dec . Hitij Nina Turnšek, Kern Izidor, Sadikov Aleksander, Knez Lea, Stani? Karmen, Zwitter Matjaž, Cufer Tan |
[Cost-effectiveness of risk-reducing salpingo-oophorectomy in cases of BRCA1 gene mutation in Colombia]. Revista de salud publica (Bogota, Colombia) 0 20 (2): 232-236. González-Mariño Mario |
Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach. European addiction research 2018 11 24 (5): 245-254. Sluiter Reinier L, Kievit Wietske, van der Wilt Gert Jan, Schene Aart H, Teichert Martina, Coenen Marieke J H, Schellekens Ar |
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clinical drug investigation 2019 Sep . Wei Xiaoxia, Sun Hong, Zhuang Jie, Weng Xiuhua, Zheng Bin, Lin Qiwang, Zhang Guifeng, Cai Jiaq |
Cost-Effectiveness of Strategies to Personalize the Selection of P2Y Inhibitors in Patients with Acute Coronary Syndrome. Cardiovascular drugs and therapy 2019 8 33 (5): 533-546. Kim Kibum, Touchette Daniel R, Cavallari Larisa H, Ardati Amer K, DiDomenico Robert |
Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. Journal of Crohn's & colitis 2019 Jan . Sluiter Reinier L, van Marrewijk Corine, de Jong Dirk, Scheffer Hans, Guchelaar Henk-Jan, Derijks Luc, Wong Dennis R, Hooymans Piet, Vermeulen Sita H, Verbeek André L M, Franke Barbara, van der Wilt Gert Jan, Kievit Wietske, Coenen Marieke J |
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics 2019 1 20 (4): 241-249. Wei XiaoXia, Cai JiaQin, Sun Hong, Li Na, Xu Chenxia, Zhang Guifeng, Sui Yuxia, Zhuang Jie, Zheng B |
Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020 3 23 (2): 180-190. Fawsitt Christopher G, Vickerman Peter, Cooke Graham S, , Welton Nicky |
Utility evaluation of HLA-B*13:01 screening in preventing trichloroethylene-induced hypersensitivity syndrome in a prospective cohort study. Occupational and environmental medicine 2020 2 77 (3): 201-206. Dai Yufei, Zhou Wei, Jia Qiang, Dong Haiyan, Niu Yong, He Jiaxi, Bin Ping, Yi Juan, Xiang Yingping, Duan Huawei, Huang Huiping, Sha Yan, Shen Meili, Ye Meng, Huang Xianqing, Zheng Yux |
Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by immunohistochemistry. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2021 Jan 46 (1): 11-17. Yu Xuemei, Mao Ruiqi, Liu Min, Fu Limei, Shi Lifang, Li Xinj |
Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. International journal of cardiology 2021 2 331 27-34. AlMukdad Sawsan, Elewa Hazem, Arafa Salaheddin, Al-Badriyeh Dao |
Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis. Value in health regional issues 2023 6 37 71-80. Soroush Ahmadi Fariman, Zahra Jahangard Rafsanjani, Mandana Hasanzad, Kimia Niksalehi, Shekoufeh Nikf |
Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Chinese clinical oncology 2023 5 . Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J Ernst, Lida A Mi |
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden. PharmacoEconomics - open 2023 12 . Maria Polyzoi, Mattias Ekman, Anja Reithmeier, Johanna Jacob, Emma Karlsson, Evelina Bertranou, Barbro Linderholm, Robert Hett |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: